summit trial tirzepatide and Cardiovascular Outcomes: A Narrative Review of Mechanisms, Efficacy and Implications for Heart Failure Management - Abdul‐Hafez - 2026 - Endocrinology, Diabetes & Metabolism In pts wiht HFpEF and

This hormone is involved in regulating our appetite, blood sugar & insulin levels and gut movements

Another Study Examines Ozempic and Other GLP-1s and NAION There are currently 146 pending lawsuits involving Ozempic and other GLP-1 drugs and NAION (vision loss)

Meyhfer of Novo Nordisk Pharma GmbH, in Germany, is the papers corresponding author and Sanyal is a co-author

p=0.0404) during low-to-moderate exercise and an early crossover of carbohydrate over lipid oxidation (4712 vs 5212 %VO 2max , p=0.0204)

Obesity: a therapeutic target in people with cardiovascular disease Obesity is a major public health problem that contributes indirectly and directly to cardiovascular disease and mortality

In May 2026 the EMAs CHMP issued a positive opinion recommending oral semaglutide 25 mg (the Wegovy pill) for weight management, the first oral GLP-1 of its kind in the EU